Aptose Biosciences closes public offering of US$21.3M in common shares
Date Closed
June 3, 2019
Lead Office
Québec City
Value
21.30 Million USD
On June 3, 2019, Aptose Biosciences ("Aptose") completed its public offering of 10,000,000 common shares at US$1.85 per shares, for aggregate gross proceeds of US$21.3 million. The public offering included the exercise in full by the underwriters of their option to purchase 1,500,000 additional common shares. RBC Capital Markets and Canaccord Genuity acted as joint book-running managers for the offering. H.C. Wainwright & Co. and JonesTrading Institutional services LLC acted as co-managers.
Aptose intends to use the proceeds from the offering to expand its clinical trial programs, and for working capital and general purposes.
Aptose, headquartered in Toronto, Ontario, is a biopharmaceutical company. It focuses on the discovery, research and development of anti-cancer therapies.
McCarthy Tétrault LLP represented Aptose, the issuer, with a team led by Charles-Antoine Soulière, that included Felipe Diaz Villegas, Vincent Laurin and Annie Poirier-Simard.
